Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)
Globe Newswire•12/11/2026•16:10 ET
0
Key Highlights
- ➤Q3 net revenue $28.4M, up 8% year-over-year
- ➤Q3 net loss $1.3M, or $0.15 per diluted share
- ➤Q3 Adjusted EBITDA $5.6M, up from $4.9M year-over-year
- ➤Full-year 2026 revenue guidance cut to $110M-$115M from $116M-$121M
- ➤Sanara expects acquisition by MiMedx after shareholder approval and ongoing regulatory review
Expert Statements
Seth Yon, President and Chief Executive Officer of Sanara MedTech
“Our team delivered another quarter of strong execution with net revenue of $28.4 million, representing 8% growth year-over-year, gross margin of 93% and Adjusted EBITDA of $5.6 million. CellerateRX Surgical and BIASURGE continue to be strong drivers of our revenue growth.”
Seth Yon, President and Chief Executive Officer of Sanara MedTech
“In July, we announced our entry into a transformational agreement in which Sanara is expected to be acquired by MIMEDX. We were pleased to receive shareholder approval for the pending combination in September, and we continue to work through the regulatory and review process. We believe this is a significant next step for Sanara’s growth and we remain excited about the opportunity this transaction represents for our customers, employees and shareholders.”
FORT WORTH, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the third quarter ended September 30, 2026.
●Net revenue increased 8% to $28.4 million, compared to $26.3 million in the third quarter of 2025.
Get started
Create a free account to read the full story.